Dizal Pharmaceutical(SH:688192) Shang Hai Zheng Quan Bao·2025-07-04 19:05Core Points - The company has completed the cancellation of certain special accounts for raised funds from its initial public offering and private placement [1][5][6] Fundraising Overview - The company raised a total of RMB 2,103,205,258.00 from its initial public offering, with a net amount of RMB 1,986,567,781.57 after deducting issuance costs [1] - The company also raised RMB 1,795,886,744.00 from a private placement, resulting in a net amount of RMB 1,773,446,130.53 after deducting issuance costs of RMB 22,440,613.47 [2] Fund Management - The company has established a management method for the use of raised funds, ensuring compliance with relevant laws and regulations, and has implemented special account management for the funds [3] Account Cancellation Details - The company has canceled several fundraising special accounts due to minimal remaining balances, transferring the remaining funds to other operational accounts [5] - The cancellation of these accounts has been completed, and the corresponding storage supervision agreements have been terminated [6]